Spyre Therapeutics(SYRE)高管介绍_美股行情

董事介绍

注：董事持股数取自最新公司公告

姓名	性别	职位	年龄	薪酬	持股数(万股)	截止日期
Jeffrey Albers	男	Independent Chair of the Board and Independent Director	54	34.87万美元	9.84	2026-05-27
Cameron Turtle	男	Director,Chief Executive Officer and Chief Operating Officer	36	670.74万美元	246.77	2026-05-27
Laurie Stelzer	女	Independent Director	59	31.37万美元	7.10	2026-05-27
Peter Harwin	男	Independent Director	40	29.37万美元	878.72	2026-05-27
Tomas Kiselak	男	Independent Director	40	29.62万美元	878.72	2026-05-27
Sandra Milligan	女	Independent Director	62	30.62万美元	3.43	2026-05-27
Michael Henderson	男	Independent Director	37	29.87万美元	27.88	2026-05-27
Mark McKenna	男	Director	46	28.87万美元	32.80	2026-05-27
Sandra Milligan	女	Independent Director	62	未披露	未持股	2026-05-27
Mark McKenna	男	Director	46	未披露	未持股	2026-05-27
Laurie Stelzer	女	Independent Director	58	未披露	未持股	2026-05-27
Jeffrey Albers	男	Independent Chair of the Board and Independent Director	54	未披露	未持股	2026-05-27
Tomas Kiselak	男	Independent Director	39	未披露	未持股	2026-05-27
Peter Harwin	男	Independent Director	40	未披露	未持股	2026-05-27
Michael Henderson	男	Independent Director	36	未披露	未持股	2026-05-27
Cameron Turtle	男	Director,Chief Executive Officer and Chief Operating Officer	36	未披露	未持股	2026-05-27

高管介绍

注：高管持股数取自最新公司公告

姓名	性别	职位	年龄	薪酬	持股数(万股)	截止日期
Cameron Turtle	男	Director,Chief Executive Officer and Chief Operating Officer	36	670.74万美元	246.77	2026-05-27
Heidy King Jones	女	Chief Legal Officer and Corporate Secretary	43	219.20万美元	42.15	2026-05-27
Sheldon Sloan	男	Chief Medical Officer	68	221.18万美元	18.66	2026-05-27
Scott Burrows	男	Chief Financial Officer	49	219.20万美元	36.40	2026-05-27
Sheldon Sloan	男	Chief Medical Officer	68	未披露	未持股	2026-05-27
Heidy King Jones	女	Chief Legal Officer and Corporate Secretary	43	未披露	未持股	2026-05-27
Cameron Turtle	男	Director,Chief Executive Officer and Chief Operating Officer	36	未披露	未持股	2026-05-27

董事简历

中英对照 | 中文 | 英文

Jeffrey Albers: Jeffrey Albers自2020年7月以来一直是我们的董事会成员。2014年7月，他加入Blueprint Medicines Corp.，担任首席执行官和董事会成员。他领导研究阶段的公司通过首次公开募股，现在是一个完全集成的全球生物技术公司。他此前曾担任Algeta ASA公司的总裁（从2012年1月到2014年4月），在那里他曾监管公司被Bayer公司收购之前靶向癌症疗法的成功商业启动。任职Algeta公司之前，他曾担任Genzyme公司（现为Sanofi公司的一个部门）的高级商业和公司开发职务（从2005年7月到2011年11月），最近担任美国血液和肿瘤业务部门的Vice President。Albers从2000年到2005年担任Mintz Levin Cohn Ferris Glovsky&Popeo生命科学公司律师。他目前任职于MagentaTherapeutics，Inc.公司（一家公开上市的生物技术公司）和美国癌症协会新英格兰东部分会的董事会，也是生命科学关怀顾问委员会的成员。他持有Indiana University的工商管理硕士学位，以及Georgetown University的工商管理硕士学位和法学博士学位。

Jeffrey Albers,has served as a member of board of directors since July 2020. He currently serves as the Chair of the board of directors of Blueprint Medicines Corp., or Blueprint, and served as Blueprint's Executive Chair from April to December 2022 and Chief Executive Officer from July 2014 to August 2022, and as a member of the board of directors since July 2014. During that time, he led the research-stage company through an initial public offering and now to a fully integrated, global biotechnology company. Mr. Albers previously served as President of Algeta ASA from January 2012 to April 2014, where he oversaw the successful commercial launch of a targeted cancer therapy prior to its acquisition by Bayer in April 2014. Prior to Algeta ASA, he held senior commercial and corporate development positions at Genzyme Corporation (now a division of Sanofi) from July 2005 to November 2011, most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career from 2000 to 2005, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves as the Chair of the board of directors of Spyre Therapeutics, a publicly traded biotechnology company and serves as a member of the board of directors of several privately held companies. He currently serves as a Venture Partner at Atlas Venture and is on the Board of Advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.; Jeffrey Albers自2020年7月以来一直是我们的董事会成员。2014年7月，他加入Blueprint Medicines Corp.，担任首席执行官和董事会成员。他领导研究阶段的公司通过首次公开募股，现在是一个完全集成的全球生物技术公司。他此前曾担任Algeta ASA公司的总裁（从2012年1月到2014年4月），在那里他曾监管公司被Bayer公司收购之前靶向癌症疗法的成功商业启动。任职Algeta公司之前，他曾担任Genzyme公司（现为Sanofi公司的一个部门）的高级商业和公司开发职务（从2005年7月到2011年11月），最近担任美国血液和肿瘤业务部门的Vice President。Albers从2000年到2005年担任Mintz Levin Cohn Ferris Glovsky&Popeo生命科学公司律师。他目前任职于MagentaTherapeutics，Inc.公司（一家公开上市的生物技术公司）和美国癌症协会新英格兰东部分会的董事会，也是生命科学关怀顾问委员会的成员。他持有Indiana University的工商管理硕士学位，以及Georgetown University的工商管理硕士学位和法学博士学位。; Jeffrey Albers,has served as a member of board of directors since July 2020. He currently serves as the Chair of the board of directors of Blueprint Medicines Corp., or Blueprint, and served as Blueprint's Executive Chair from April to December 2022 and Chief Executive Officer from July 2014 to August 2022, and as a member of the board of directors since July 2014. During that time, he led the research-stage company through an initial public offering and now to a fully integrated, global biotechnology company. Mr. Albers previously served as President of Algeta ASA from January 2012 to April 2014, where he oversaw the successful commercial launch of a targeted cancer therapy prior to its acquisition by Bayer in April 2014. Prior to Algeta ASA, he held senior commercial and corporate development positions at Genzyme Corporation (now a division of Sanofi) from July 2005 to November 2011, most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career from 2000 to 2005, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves as the Chair of the board of directors of Spyre Therapeutics, a publicly traded biotechnology company and serves as a member of the board of directors of several privately held companies. He currently serves as a Venture Partner at Atlas Venture and is on the Board of Advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

Cameron Turtle: Cameron Turtle自2018年1月以来一直担任我们的高级副总裁，投资组合管理和企业发展，并于2017年2月至2017年12月担任投资组合管理董事。Turtle先生自2017年2月起还曾在我们的子公司Eidos Therapeutics工作，目前担任首席商务官。Turtle先生曾于2017年2月至2018年3月担任我们的子公司Navire Pharmaceuticals，Inc.的业务开发和运营Vice President。从2016年8月至2017年1月，乌龟先生是麦肯锡公司的顾问。Turtle先生在华盛顿大学（University of Washington）以优异成绩获得生物工程学士学位，并获得哲学博士学位。他在牛津大学圣约翰学院（University of Oxford，St.John&8217；s College）获得心血管医学博士学位，在那里他曾是一名罗德学者。

Cameron Turtle has served as BridgeBio Pharma, Inc. Senior Vice President, Portfolio Management and Corporate Development, since January 2018 and served as a Director, Portfolio Management, from February 2017 to December 2017. Mr. Turtle has also worked for BridgeBio Pharma, Inc. subsidiary, Eidos Therapeutics, since February 2017 currently as the chief business officer. Mr. Turtle previously worked as vice president of business development and operations for BridgeBio Pharma, Inc. subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017 Mr. Turtle was a consultant at McKinsey & Company. Mr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John's College, where he was a Rhodes Scholar.; Cameron Turtle自2018年1月以来一直担任我们的高级副总裁，投资组合管理和企业发展，并于2017年2月至2017年12月担任投资组合管理董事。Turtle先生自2017年2月起还曾在我们的子公司Eidos Therapeutics工作，目前担任首席商务官。Turtle先生曾于2017年2月至2018年3月担任我们的子公司Navire Pharmaceuticals，Inc.的业务开发和运营Vice President。从2016年8月至2017年1月，乌龟先生是麦肯锡公司的顾问。Turtle先生在华盛顿大学（University of Washington）以优异成绩获得生物工程学士学位，并获得哲学博士学位。他在牛津大学圣约翰学院（University of Oxford，St.John&8217；s College）获得心血管医学博士学位，在那里他曾是一名罗德学者。; Cameron Turtle has served as BridgeBio Pharma, Inc. Senior Vice President, Portfolio Management and Corporate Development, since January 2018 and served as a Director, Portfolio Management, from February 2017 to December 2017. Mr. Turtle has also worked for BridgeBio Pharma, Inc. subsidiary, Eidos Therapeutics, since February 2017 currently as the chief business officer. Mr. Turtle previously worked as vice president of business development and operations for BridgeBio Pharma, Inc. subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017 Mr. Turtle was a consultant at McKinsey & Company. Mr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John's College, where he was a Rhodes Scholar.

Laurie Stelzer: Laurie Stelzer自2020年8月起担任我们的董事会成员。Stelzer女士曾担任ArenaPharmaceuticals，Inc.执行Vice President和首席财务官纳斯达克:ARNA，生物制药公司，自2020年3月起。她还自2018年1月起担任临床阶段免疫肿瘤公司SurfaceOncology，Inc.（纳斯达克股票代码:SURF）的董事会成员。在加入Arena Pharmaceuticals之前，Stelzer女士于2015年6月至2020年3月担任生物制药技术平台公司HalozymeTherapeutics，Inc.（纳斯达克股票代码:HALO）的首席财务官，领导财务，信息技术，业务开发，项目管理和现场运营组织。在加入Halozyme Therapeutics之前，Stelzer女士曾在Shire plc（被武田收购）担任高级管理职务，包括财务高级副总裁、再生医学部门的部门首席财务官和投资者关系主管。此前，她也曾任职Amgen，Inc.（纳斯达克股票代码:AMGN）（全球生物制药公司）15年，担任财务、财政、全球会计和国际/新兴市场领域的责任日益增加的职务。Stelzer女士在亚利桑那州立大学（Arizona State University）获得会计学学士学位，并在加州大学洛杉矶分校安德森管理学院（Anderson School of Management）获得工商管理硕士学位。

Laurie Stelzer,has served as a member of Sionna Therapeutics, Inc. board of directors since November 2024. Ms. Stelzer has served as the Chief Financial Officer of Kailera Therapeutics, Inc. ("Kailera") since January 2025. Prior to Kailera, Ms. Stelzer served as the Chief Financial Officer of Orna Therapeutics ("Orna") from May 2024 to January 2025. Prior to Orna, Ms. Stelzer served as the Chief Financial Officer of ReNAgade Therapeutics, Inc. ("ReNAgade") from September 2023 until the completion of its acquisition by Orna in May 2024. Prior to joining ReNAgade, Ms. Stelzer served as the Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX) ("Mirati Therapeutics") from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as the Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena Pharmaceuticals") (acquired by Pfizer) from March 2020 until the completion of Pfizer's acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as the Chief Financial Officer at Halozyme Therapeutics, Inc. ("Halozyme Therapeutics") (Nasdaq: HALO) from June 2015 to March 2020, and before Halozyme Therapeutics, she held senior management roles at Shire Plc (acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK)) and Amgen, Inc. Ms. Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) since 2020, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since 2023, Surface Oncology, Inc. (Nasdaq: SURF) from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management.; Laurie Stelzer自2020年8月起担任我们的董事会成员。Stelzer女士曾担任ArenaPharmaceuticals，Inc.执行Vice President和首席财务官纳斯达克:ARNA，生物制药公司，自2020年3月起。她还自2018年1月起担任临床阶段免疫肿瘤公司SurfaceOncology，Inc.（纳斯达克股票代码:SURF）的董事会成员。在加入Arena Pharmaceuticals之前，Stelzer女士于2015年6月至2020年3月担任生物制药技术平台公司HalozymeTherapeutics，Inc.（纳斯达克股票代码:HALO）的首席财务官，领导财务，信息技术，业务开发，项目管理和现场运营组织。在加入Halozyme Therapeutics之前，Stelzer女士曾在Shire plc（被武田收购）担任高级管理职务，包括财务高级副总裁、再生医学部门的部门首席财务官和投资者关系主管。此前，她也曾任职Amgen，Inc.（纳斯达克股票代码:AMGN）（全球生物制药公司）15年，担任财务、财政、全球会计和国际/新兴市场领域的责任日益增加的职务。Stelzer女士在亚利桑那州立大学（Arizona State University）获得会计学学士学位，并在加州大学洛杉矶分校安德森管理学院（Anderson School of Management）获得工商管理硕士学位。; Laurie Stelzer,has served as a member of Sionna Therapeutics, Inc. board of directors since November 2024. Ms. Stelzer has served as the Chief Financial Officer of Kailera Therapeutics, Inc. ("Kailera") since January 2025. Prior to Kailera, Ms. Stelzer served as the Chief Financial Officer of Orna Therapeutics ("Orna") from May 2024 to January 2025. Prior to Orna, Ms. Stelzer served as the Chief Financial Officer of ReNAgade Therapeutics, Inc. ("ReNAgade") from September 2023 until the completion of its acquisition by Orna in May 2024. Prior to joining ReNAgade, Ms. Stelzer served as the Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX) ("Mirati Therapeutics") from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as the Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena Pharmaceuticals") (acquired by Pfizer) from March 2020 until the completion of Pfizer's acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as the Chief Financial Officer at Halozyme Therapeutics, Inc. ("Halozyme Therapeutics") (Nasdaq: HALO) from June 2015 to March 2020, and before Halozyme Therapeutics, she held senior management roles at Shire Plc (acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK)) and Amgen, Inc. Ms. Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) since 2020, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since 2023, Surface Oncology, Inc. (Nasdaq: SURF) from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management.

Peter Harwin: Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。

Peter Harwin has served as a member of Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University.; Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。; Peter Harwin has served as a member of Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University.

Tomas Kiselak: Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。

Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College.; Tomas Kiselak自2024年11月起担任Korsana董事会成员。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是他于2016年4月共同创立的一家医疗投资公司。在加入Fairmount之前，他是医疗保健和生命科学投资公司RA Capital Management，LLC的董事总经理。Kiselak先生目前担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2020年10月起担任Viridian的董事会成员，并自2023年6月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO）的董事，自2023年6月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE），自2020年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得了神经科学和经济学学士学位。; Tomas Kiselak has served as a member of the Korsana board of directors since November 2024. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian's board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr. Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College.

Sandra Milligan: Sandra Milligan，是Organon的执行副总裁兼研发负责人，负责推动差异化的药物和解决方案组合，以帮助女性和所有患者每天过上更好、更健康的生活。Milligan 博士的职责是监督该组织的科学、医学和监管能力，以支持其多样化的投资组合和长期愿景。在加入Organon之前，Milligan博士从2015年起担任默克高级副总裁兼全球监管事务和临床安全主管。此前，她曾担任Genentech的产品开发监管副总裁，2002年至2012年，她在安进公司担任法律和监管事务职能部门的职务。1987年至1994年，Milligan 博士在美国陆军医疗队服役。Milligan博士自2021起一直担任临床阶段生物制药公司Gossamer Bio，Inc.的董事会成员，2011年至2017年担任药物信息协会DIA的董事会成员，包括担任主席，现在是DIA研究员。Milligan 博士致力于培养多元化的领导力，曾担任默克女性领导力项目的联合赞助商。Milligan 博士获得了乔治华盛顿大学医学院的医学学位、乔治敦大学法律中心的法学博士学位、加州大学欧文分校的生物学学士学位和心理学学士学位。

Sandra Milligan,leads the advancement of a differentiated portfolio of medicines and solutions to help women and all patients live a better and healthier every day. In her role, Dr. Milligan oversees the organization's scientific, medical and regulatory capabilities in support of its diverse portfolio and long-term vision. Before joining Organon, from 2015, Dr. Milligan served as Merck's Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety. Previously, she served as Vice President of Product Development Regulatory for Genentech, and from 2002 to 2012, she was at Amgen Inc. in positions of increasing responsibility across legal and regulatory affairs functions. Dr. Milligan served in the U.S. Army Medical Corps from 1987 to 1994. Dr. Milligan has been on the board of directors of Gossamer Bio, Inc., a clinical stage biopharmaceutical company, since 2021, and was on the board of directors of the Drug Information Association (DIA) from 2011 to 2017, including serving as Chair, and is now a DIA fellow. With a deep commitment to fostering diverse leadership, Dr. Milligan has served as co-sponsor of the Merck Women's Leadership Program. Dr. Milligan received a medical degree from George Washington University School of Medicine, a J.D. from the Georgetown University School of Law and bachelor of science degree in biology and a bachelor of arts degree in psychology from the University of California, Irvine.; Sandra Milligan，是Organon的执行副总裁兼研发负责人，负责推动差异化的药物和解决方案组合，以帮助女性和所有患者每天过上更好、更健康的生活。Milligan 博士的职责是监督该组织的科学、医学和监管能力，以支持其多样化的投资组合和长期愿景。在加入Organon之前，Milligan博士从2015年起担任默克高级副总裁兼全球监管事务和临床安全主管。此前，她曾担任Genentech的产品开发监管副总裁，2002年至2012年，她在安进公司担任法律和监管事务职能部门的职务。1987年至1994年，Milligan 博士在美国陆军医疗队服役。Milligan博士自2021起一直担任临床阶段生物制药公司Gossamer Bio，Inc.的董事会成员，2011年至2017年担任药物信息协会DIA的董事会成员，包括担任主席，现在是DIA研究员。Milligan 博士致力于培养多元化的领导力，曾担任默克女性领导力项目的联合赞助商。Milligan 博士获得了乔治华盛顿大学医学院的医学学位、乔治敦大学法律中心的法学博士学位、加州大学欧文分校的生物学学士学位和心理学学士学位。; Sandra Milligan,leads the advancement of a differentiated portfolio of medicines and solutions to help women and all patients live a better and healthier every day. In her role, Dr. Milligan oversees the organization's scientific, medical and regulatory capabilities in support of its diverse portfolio and long-term vision. Before joining Organon, from 2015, Dr. Milligan served as Merck's Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety. Previously, she served as Vice President of Product Development Regulatory for Genentech, and from 2002 to 2012, she was at Amgen Inc. in positions of increasing responsibility across legal and regulatory affairs functions. Dr. Milligan served in the U.S. Army Medical Corps from 1987 to 1994. Dr. Milligan has been on the board of directors of Gossamer Bio, Inc., a clinical stage biopharmaceutical company, since 2021, and was on the board of directors of the Drug Information Association (DIA) from 2011 to 2017, including serving as Chair, and is now a DIA fellow. With a deep commitment to fostering diverse leadership, Dr. Milligan has served as co-sponsor of the Merck Women's Leadership Program. Dr. Milligan received a medical degree from George Washington University School of Medicine, a J.D. from the Georgetown University School of Law and bachelor of science degree in biology and a bachelor of arts degree in psychology from the University of California, Irvine.

Michael Henderson: Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。

Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.; Michael Henderson，自2023年6月起担任Apogee Therapeutics，Inc.董事会成员，自2022年起担任Apogee Therapeutics，LLC管理委员会成员，自2022年9月起担任Apogee Therapeutics，Inc.首席执行官。亨德森博士是一位经验丰富的生物技术高管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他领导了多家公司的创建，启动了大量的药物开发项目，并带领团队获得了两项FDA的批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月担任处于商业化阶段的生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，确定和投资新技术，并负责业务开发和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。亨德森博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。亨德森博士还曾担任BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，亨德森博士于2015年1月至2016年4月在全球管理咨询公司麦肯锡工作，在此之前，他于2011年8月与他人共同创立了生物技术公司PellePharm，Inc.。亨德森博士自2021年2月起担任专注于医疗保健行业的特殊目的收购公司ARYA科学并购公司IV（纳斯达克：ARYD）的董事会成员，自2023年6月起担任生物技术公司Aeglea BioTherapeutics，Inc.（纳斯达克：AGLE）的董事会成员。亨德森博士在哈佛大学获得了全球健康学士学位，在斯坦福大学获得了医学博士学位。; Michael Henderson,has served as a member of Apogee Therapeutics, Inc. Board since June 2023, as a member of the board of managers of Apogee Therapeutics, LLC since 2022 and as Apogee Therapeutics, Inc. Chief Executive Officer since September 2022. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021 and Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a biotechnology company, since June 2023. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.

Mark McKenna: 马克·麦肯纳，是导演提名人选。McKenna先生于2019-2023年担任Prometheus Biosciences（纳斯达克：RXDX）的董事长兼首席执行官。Prometheus Biosciences是一家临床阶段的生物制药公司，该公司创造了首个免疫介导疾病的精准疗法，这是Pre-Phase 3公司最大的并购收购。麦肯纳先生目前担任Apogee Therapeutics（NASDAQ：APGE）董事会主席以及麦肯纳资本合伙公司（McKenna Capital Partners）的首席投资官和董事总经理，该公司是一家致力于投资于使人衰弱的疾病的突破性治疗的家族办公室。在加入Prometheus之前，McKenna先生是Bausch Health的公司高管，并于2016年至2019年担任子公司柳药医疗的总裁。此前，麦肯纳先生曾于2006年至2016年在Bausch + Lomb任职。2002年至2006年，他的职业生涯始于强生。McKenna先生拥有亚利桑那州立大学市场营销学位和Azusa太平洋大学MBA学位。麦肯纳还在沃顿商学院完成了沃顿商学院的研究员课程。

Mark McKenna has served as a Director since January 2026. He also served as Director of Helix II from February 2024 until Helix II completed its business combination with BBOT in August 2025. Prior to that, Mr. McKenna served as Chairman and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX) from 2019 2023. Prometheus Biosciences was a clinical stage biopharmaceutical company which created the first precision therapeutics for immune mediated diseases which was the largest M&A takeout of pre phase 3 company. Mr. McKenna currently serves as the Chairman of the Board of Apogee Therapeutics (Nasdaq: APGE) and Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of the subsidiary Salix Pharmaceuticals from 2016 to 2019. Earlier, Mr. McKenna served at Bausch + Lomb from 2006 to 2016. He began his career at Johnson & Johnson from 2002 to 2006. Mr. McKenna holds a degree in Marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton's Fellows program at the Wharton School of Business.; 马克·麦肯纳，是导演提名人选。McKenna先生于2019-2023年担任Prometheus Biosciences（纳斯达克：RXDX）的董事长兼首席执行官。Prometheus Biosciences是一家临床阶段的生物制药公司，该公司创造了首个免疫介导疾病的精准疗法，这是Pre-Phase 3公司最大的并购收购。麦肯纳先生目前担任Apogee Therapeutics（NASDAQ：APGE）董事会主席以及麦肯纳资本合伙公司（McKenna Capital Partners）的首席投资官和董事总经理，该公司是一家致力于投资于使人衰弱的疾病的突破性治疗的家族办公室。在加入Prometheus之前，McKenna先生是Bausch Health的公司高管，并于2016年至2019年担任子公司柳药医疗的总裁。此前，麦肯纳先生曾于2006年至2016年在Bausch + Lomb任职。2002年至2006年，他的职业生涯始于强生。McKenna先生拥有亚利桑那州立大学市场营销学位和Azusa太平洋大学MBA学位。麦肯纳还在沃顿商学院完成了沃顿商学院的研究员课程。; Mark McKenna has served as a Director since January 2026. He also served as Director of Helix II from February 2024 until Helix II completed its business combination with BBOT in August 2025. Prior to that, Mr. McKenna served as Chairman and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX) from 2019 2023. Prometheus Biosciences was a clinical stage biopharmaceutical company which created the first precision therapeutics for immune mediated diseases which was the largest M&A takeout of pre phase 3 company. Mr. McKenna currently serves as the Chairman of the Board of Apogee Therapeutics (Nasdaq: APGE) and Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of the subsidiary Salix Pharmaceuticals from 2016 to 2019. Earlier, Mr. McKenna served at Bausch + Lomb from 2006 to 2016. He began his career at Johnson & Johnson from 2002 to 2006. Mr. McKenna holds a degree in Marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton's Fellows program at the Wharton School of Business.

Sandra Milligan: Sandra Milligan自2024年5月起担任董事。Milligan博士自2025年2月起担任Daiichi Sankyo，Inc.全球监管事务高级副总裁。在加入Daiichi之前，Milligan博士曾于2024年12月至2025年1月担任Aspira Women's Health（纳斯达克：AWH）的临时首席执行官，该公司是一家基于生物分析的女性健康公司，专注于开发妇科疾病诊断工具，并于2024年4月至2025年2月担任总裁。此前，2020年至2024年，Milligan博士曾担任全球医疗保健公司Organon & Co.（NYSE：OGN）的研发主管，并于2015年至2020年担任全球TERM5公司默沙东 & Co.（NYSE：MRK）的高级副总裁兼全球监管事务和临床安全主管。在此之前，2012年至2015年，她在生物技术公司基因泰克担任产品开发监管副总裁。2002年至2012年，她在生物技术公司安进公司（AMGN）担任法律和监管事务职能部门的职责越来越重的职位。米利根博士曾于1987年至1994年在美国陆军医疗队服役。Milligan博士自2021年6月起担任生物制药公司Gossamer Bio, Inc.（纳斯达克：GOSS）的董事会成员。Milligan博士在2011年至2017年期间担任药物信息协会（DIA）的董事会成员，包括担任主席，现在是DIA研究员。Milligan博士在加州大学欧文分校获得生物学学士学位和心理学学士学位。此外，她毕业于乔治华盛顿大学医学院，并获得了乔治城大学法律中心的法学博士学位。

Sandra Milligan has served as a director since May 2024. Dr. Milligan has served as SVP, Global Regulatory Affairs of Daiichi Sankyo, Inc. since February 2025. Prior to joining Daiichi, Dr. Milligan served as Interim CEO of Aspira Women's Health (Nasdaq: AWH), a bio analytical based women's health company focused on the development of gynecologic disease diagnostic tools, from December 2024 to January 2025, and as President from April 2024 to February 2025. Previously, from 2020 to 2024, Dr. Milligan served as the Head of Research and Development of Organon & Co. (NYSE: OGN), a global healthcare company, and, from 2015 to 2020, as Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety of Merck & Co. (NYSE: MRK), a global healthcare company. Previously, from 2012 to 2015, she served as Vice President of Product Development Regulatory for Genentech, Inc., a biotechnology company, and, from 2002 to 2012, she was at Amgen Inc. (Nasdaq: AMGN), a biotechnology company, in positions of increasing responsibility across legal and regulatory affairs functions. Dr. Milligan served in the United States Army Medical Corps from 1987 to 1994. Dr. Milligan has served as a member of the board of directors of Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company, since June 2021. Dr. Milligan was on the board of directors of the Drug Information Association, or DIA, from 2011 to 2017, including serving as chair, and is now a DIA fellow. Dr. Milligan received a B.S. in Biology and a B.A. in Psychology from the University of California, Irvine. Additionally, she is a graduate of George Washington University School of Medicine and received a J.D. from the Georgetown University Law Center.; Sandra Milligan自2024年5月起担任董事。Milligan博士自2025年2月起担任Daiichi Sankyo，Inc.全球监管事务高级副总裁。在加入Daiichi之前，Milligan博士曾于2024年12月至2025年1月担任Aspira Women's Health（纳斯达克：AWH）的临时首席执行官，该公司是一家基于生物分析的女性健康公司，专注于开发妇科疾病诊断工具，并于2024年4月至2025年2月担任总裁。此前，2020年至2024年，Milligan博士曾担任全球医疗保健公司Organon & Co.（NYSE：OGN）的研发主管，并于2015年至2020年担任全球TERM5公司默沙东 & Co.（NYSE：MRK）的高级副总裁兼全球监管事务和临床安全主管。在此之前，2012年至2015年，她在生物技术公司基因泰克担任产品开发监管副总裁。2002年至2012年，她在生物技术公司安进公司（AMGN）担任法律和监管事务职能部门的职责越来越重的职位。米利根博士曾于1987年至1994年在美国陆军医疗队服役。Milligan博士自2021年6月起担任生物制药公司Gossamer Bio, Inc.（纳斯达克：GOSS）的董事会成员。Milligan博士在2011年至2017年期间担任药物信息协会（DIA）的董事会成员，包括担任主席，现在是DIA研究员。Milligan博士在加州大学欧文分校获得生物学学士学位和心理学学士学位。此外，她毕业于乔治华盛顿大学医学院，并获得了乔治城大学法律中心的法学博士学位。; Sandra Milligan has served as a director since May 2024. Dr. Milligan has served as SVP, Global Regulatory Affairs of Daiichi Sankyo, Inc. since February 2025. Prior to joining Daiichi, Dr. Milligan served as Interim CEO of Aspira Women's Health (Nasdaq: AWH), a bio analytical based women's health company focused on the development of gynecologic disease diagnostic tools, from December 2024 to January 2025, and as President from April 2024 to February 2025. Previously, from 2020 to 2024, Dr. Milligan served as the Head of Research and Development of Organon & Co. (NYSE: OGN), a global healthcare company, and, from 2015 to 2020, as Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety of Merck & Co. (NYSE: MRK), a global healthcare company. Previously, from 2012 to 2015, she served as Vice President of Product Development Regulatory for Genentech, Inc., a biotechnology company, and, from 2002 to 2012, she was at Amgen Inc. (Nasdaq: AMGN), a biotechnology company, in positions of increasing responsibility across legal and regulatory affairs functions. Dr. Milligan served in the United States Army Medical Corps from 1987 to 1994. Dr. Milligan has served as a member of the board of directors of Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company, since June 2021. Dr. Milligan was on the board of directors of the Drug Information Association, or DIA, from 2011 to 2017, including serving as chair, and is now a DIA fellow. Dr. Milligan received a B.S. in Biology and a B.A. in Psychology from the University of California, Irvine. Additionally, she is a graduate of George Washington University School of Medicine and received a J.D. from the Georgetown University Law Center.

Mark McKenna: 马克·麦肯纳自2024年2月起担任董事。麦肯纳先生是生物技术公司Mirador Therapeutics，Inc.的创始人，自2024年3月起担任其董事长兼首席执行官。McKenna先生还自2023年8月起担任生物技术公司Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事会主席，并自2024年7月起担任临床生物制药公司New Amsterdam Pharma（纳斯达克：NAMS）的董事。此外，McKenna先生自2024年2月起担任投资公司Arch Venture Partners的风险合伙人，自2023年10月起担任医疗保健投资公司Fairmount Funds Management LLC的高级顾问。在加入Mirador之前，McKenna先生曾于2019年9月至2023年6月担任临床阶段生物技术公司Prometheus Biosciences, Inc.的总裁兼首席执行官和董事会成员，当时Prometheus被默沙东 & Co，Inc.收购，并于2021年8月至2023年6月担任Prometheus董事会主席。在加入Prometheus之前，McKenna先生是Bausch Health Companies，Inc.的公司高管，并于2016年3月至2019年8月期间担任其子公司——制药公司柳药医疗制药公司的总裁。在加入柳药医疗之前，McKenna先生曾在Bausch + Lomb（也是Bausch Health公司的一个部门）担任过十多年的各种职务，最近担任高级副总裁兼美国视力保健业务总经理。McKenna先生拥有亚利桑那州立大学市场营销学士学位和Azusa太平洋大学工商管理硕士学位。麦肯纳先生是安永会计师事务所2023年的年度企业家。

Mark McKenna has served as a director since February 2024. Mr. McKenna is the founder of Mirador Therapeutics, Inc., a biotechnology company, and has served as its Chairman and Chief Executive Officer since March 2024. Mr. McKenna has also served as chairman of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since August 2023 and a director at New Amsterdam Pharma (Nasdaq: NAMS), a clinical biopharmaceutical company, since July 2024. In addition, Mr. McKenna has served as a venture partner at Arch Venture Partners, an investment firm, since February 2024 and Senior Advisor at Fairmount Funds Management LLC, a healthcare investment firm, since October 2023. Prior to Mirador, Mr. McKenna served as the President and Chief Executive Officer and a member of the board of directors of Prometheus Biosciences, Inc., a clinical stage biotechnology company, from September 2019 to June 2023, when Prometheus was acquired by Merck & Co, Inc. and as Chairman of the board of Prometheus from August 2021 to June 2023. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health Companies, Inc. and served as President of its subsidiary, Salix Pharmaceuticals, Inc., a pharmaceutical company, from March 2016 through August 2019. Prior to Salix Pharmaceuticals, Mr. McKenna spent more than a decade in various roles with Bausch + Lomb, also a division of Bausch Health Companies, Inc., most recently as Senior Vice President and General Manager of its U.S. Vision Care business. Mr. McKenna holds a B.S. in marketing from Arizona State University and an M.B.A. from Azusa Pacific University. Mr. McKenna was Ernst & Young's Entrepreneur of the Year in 2023.; 马克·麦肯纳自2024年2月起担任董事。麦肯纳先生是生物技术公司Mirador Therapeutics，Inc.的创始人，自2024年3月起担任其董事长兼首席执行官。McKenna先生还自2023年8月起担任生物技术公司Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事会主席，并自2024年7月起担任临床生物制药公司New Amsterdam Pharma（纳斯达克：NAMS）的董事。此外，McKenna先生自2024年2月起担任投资公司Arch Venture Partners的风险合伙人，自2023年10月起担任医疗保健投资公司Fairmount Funds Management LLC的高级顾问。在加入Mirador之前，McKenna先生曾于2019年9月至2023年6月担任临床阶段生物技术公司Prometheus Biosciences, Inc.的总裁兼首席执行官和董事会成员，当时Prometheus被默沙东 & Co，Inc.收购，并于2021年8月至2023年6月担任Prometheus董事会主席。在加入Prometheus之前，McKenna先生是Bausch Health Companies，Inc.的公司高管，并于2016年3月至2019年8月期间担任其子公司——制药公司柳药医疗制药公司的总裁。在加入柳药医疗之前，McKenna先生曾在Bausch + Lomb（也是Bausch Health公司的一个部门）担任过十多年的各种职务，最近担任高级副总裁兼美国视力保健业务总经理。McKenna先生拥有亚利桑那州立大学市场营销学士学位和Azusa太平洋大学工商管理硕士学位。麦肯纳先生是安永会计师事务所2023年的年度企业家。; Mark McKenna has served as a director since February 2024. Mr. McKenna is the founder of Mirador Therapeutics, Inc., a biotechnology company, and has served as its Chairman and Chief Executive Officer since March 2024. Mr. McKenna has also served as chairman of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since August 2023 and a director at New Amsterdam Pharma (Nasdaq: NAMS), a clinical biopharmaceutical company, since July 2024. In addition, Mr. McKenna has served as a venture partner at Arch Venture Partners, an investment firm, since February 2024 and Senior Advisor at Fairmount Funds Management LLC, a healthcare investment firm, since October 2023. Prior to Mirador, Mr. McKenna served as the President and Chief Executive Officer and a member of the board of directors of Prometheus Biosciences, Inc., a clinical stage biotechnology company, from September 2019 to June 2023, when Prometheus was acquired by Merck & Co, Inc. and as Chairman of the board of Prometheus from August 2021 to June 2023. Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health Companies, Inc. and served as President of its subsidiary, Salix Pharmaceuticals, Inc., a pharmaceutical company, from March 2016 through August 2019. Prior to Salix Pharmaceuticals, Mr. McKenna spent more than a decade in various roles with Bausch + Lomb, also a division of Bausch Health Companies, Inc., most recently as Senior Vice President and General Manager of its U.S. Vision Care business. Mr. McKenna holds a B.S. in marketing from Arizona State University and an M.B.A. from Azusa Pacific University. Mr. McKenna was Ernst & Young's Entrepreneur of the Year in 2023.

Laurie Stelzer: Laurie Stelzer自2023年11月起担任董事。Stelzer女士于2025年1月至2025年10月期间担任Kailera Therapeutics，Inc.的首席财务官，该公司是一家专注于开发肥胖疗法的生物技术公司。在加入Kailera之前，Stelzer女士于2024年5月至2025年1月在Orna Therapeutics，Inc.（一家专注于RNA疗法的生物技术公司）担任首席财务官。在加入Orna之前，Stelzer女士于2023年9月至2024年5月期间担任ReNagade Therapeutics，Inc.的首席财务官，该公司是一家专注于RNA疗法的生物技术公司。在加入ReNAGade之前，Stelzer女士于2022年5月至2023年9月期间担任Mirati Therapeutics, Inc.（MRTX）的首席财务官，该公司是一家商业阶段的靶向肿瘤学公司。在加入Mirati Therapeutics之前，Stelzer女士于2020年3月至2022年3月完成对辉瑞的收购之前，曾担任生物制药公司Arena Pharmaceuticals, Inc.（已被辉瑞公司收购）的执行副总裁兼首席财务官。在加入阿里那制药之前，Stelzer女士于2015年6月至2020年3月在生物制药技术平台公司Halozyme Therapeutics, Inc.，Inc.（纳斯达克：HALO）担任首席财务官，负责领导财务、信息技术、业务发展、项目管理和现场运营组织。在加入奥洛兹美医疗之前，Stelzer女士曾在Shire plc（被武田制药收购）担任高级管理职务，包括财务高级副总裁、再生医学部门的部门首席财务官以及投资者关系主管。此前，她还曾在全球生物制药公司安进公司（纳斯达克：AMGN）工作了15年，在金融、财务、全球会计和国际/新兴市场领域担任越来越重要的职务。Stelzer女士曾担任MBX Biosciences，Inc.（纳斯达克：MBX）的董事会成员，该公司是一家临床阶段的生物制药公司，自2026年1月起，Sionna Therapeutics（纳斯达克：SION）是一家临床阶段的囊性纤维化公司，自2024年起，精准肿瘤学公司PMVTERM2 Pharmaceuticals，Inc.（纳斯达克：PMVP）自2020年起，临床阶段免疫肿瘤学公司Surface Oncology, Inc.（纳斯达克：SURF）自2018年起至2023年9月被Coherus收购，2020年至2021年被临床阶段神经病学公司Longboard Pharmaceuticals收购。Stelzer女士在亚利桑那州立大学获得会计学学士学位，在加州大学洛杉矶分校安德森管理学院获得工商管理硕士学位。

Laurie Stelzer has served as a director since November 2023. Ms. Stelzer served as Chief Financial Officer of Kailera Therapeutics, Inc., a biotechnology company focused on developing therapies for obesity, from January 2025 to October 2025. Prior to joining Kailera, Ms. Stelzer served as Chief Financial Officer of Orna Therapeutics, Inc., a biotechnology company focused on RNA therapeutics, from May 2024 to January 2025. Prior to joining Orna, Ms. Stelzer served as Chief Financial Officer of ReNAgade Therapeutics, Inc., a biotechnology company focused on RNA therapeutics, from September 2023 to May 2024. Prior to joining ReNAgade, Ms. Stelzer served as Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage targeted oncology company, from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. (acquired by Pfizer Inc.), a biopharmaceutical company, from March 2020 until the completion of Pfizer's acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as Chief Financial Officer at Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharma technology platform company, from June 2015 to March 2020, where she led the Finance, Information Technology, Business Development, Project Management and Site Operations organizations. Prior to joining Halozyme Therapeutics, Ms. Stelzer held senior management roles at Shire Plc (acquired by Takeda Pharmaceutical), including Senior Vice President of Finance, Division Chief Financial Officer for the Regenerative Medicine Division and Head of Investor Relations. Previously, she also worked at Amgen, Inc. (Nasdaq: AMGN), a global biopharmaceutical company, for 15 years, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms. Stelzer has served as a member of the board of directors of MBX Biosciences, Inc. (Nasdaq: MBX), a clinical stage biopharmaceutical company, since January 2026, Sionna Therapeutics (Nasdaq: SION), a clinical stage cystic fibrosis company, since 2024, PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company, since 2020, Surface Oncology, Inc. (Nasdaq: SURF), a clinical stage immune oncology company, from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals, a clinical stage neurology company from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management.; Laurie Stelzer自2023年11月起担任董事。Stelzer女士于2025年1月至2025年10月期间担任Kailera Therapeutics，Inc.的首席财务官，该公司是一家专注于开发肥胖疗法的生物技术公司。在加入Kailera之前，Stelzer女士于2024年5月至2025年1月在Orna Therapeutics，Inc.（一家专注于RNA疗法的生物技术公司）担任首席财务官。在加入Orna之前，Stelzer女士于2023年9月至2024年5月期间担任ReNagade Therapeutics，Inc.的首席财务官，该公司是一家专注于RNA疗法的生物技术公司。在加入ReNAGade之前，Stelzer女士于2022年5月至2023年9月期间担任Mirati Therapeutics, Inc.（MRTX）的首席财务官，该公司是一家商业阶段的靶向肿瘤学公司。在加入Mirati Therapeutics之前，Stelzer女士于2020年3月至2022年3月完成对辉瑞的收购之前，曾担任生物制药公司Arena Pharmaceuticals, Inc.（已被辉瑞公司收购）的执行副总裁兼首席财务官。在加入阿里那制药之前，Stelzer女士于2015年6月至2020年3月在生物制药技术平台公司Halozyme Therapeutics, Inc.，Inc.（纳斯达克：HALO）担任首席财务官，负责领导财务、信息技术、业务发展、项目管理和现场运营组织。在加入奥洛兹美医疗之前，Stelzer女士曾在Shire plc（被武田制药收购）担任高级管理职务，包括财务高级副总裁、再生医学部门的部门首席财务官以及投资者关系主管。此前，她还曾在全球生物制药公司安进公司（纳斯达克：AMGN）工作了15年，在金融、财务、全球会计和国际/新兴市场领域担任越来越重要的职务。Stelzer女士曾担任MBX Biosciences，Inc.（纳斯达克：MBX）的董事会成员，该公司是一家临床阶段的生物制药公司，自2026年1月起，Sionna Therapeutics（纳斯达克：SION）是一家临床阶段的囊性纤维化公司，自2024年起，精准肿瘤学公司PMVTERM2 Pharmaceuticals，Inc.（纳斯达克：PMVP）自2020年起，临床阶段免疫肿瘤学公司Surface Oncology, Inc.（纳斯达克：SURF）自2018年起至2023年9月被Coherus收购，2020年至2021年被临床阶段神经病学公司Longboard Pharmaceuticals收购。Stelzer女士在亚利桑那州立大学获得会计学学士学位，在加州大学洛杉矶分校安德森管理学院获得工商管理硕士学位。; Laurie Stelzer has served as a director since November 2023. Ms. Stelzer served as Chief Financial Officer of Kailera Therapeutics, Inc., a biotechnology company focused on developing therapies for obesity, from January 2025 to October 2025. Prior to joining Kailera, Ms. Stelzer served as Chief Financial Officer of Orna Therapeutics, Inc., a biotechnology company focused on RNA therapeutics, from May 2024 to January 2025. Prior to joining Orna, Ms. Stelzer served as Chief Financial Officer of ReNAgade Therapeutics, Inc., a biotechnology company focused on RNA therapeutics, from September 2023 to May 2024. Prior to joining ReNAgade, Ms. Stelzer served as Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage targeted oncology company, from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. (acquired by Pfizer Inc.), a biopharmaceutical company, from March 2020 until the completion of Pfizer's acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as Chief Financial Officer at Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharma technology platform company, from June 2015 to March 2020, where she led the Finance, Information Technology, Business Development, Project Management and Site Operations organizations. Prior to joining Halozyme Therapeutics, Ms. Stelzer held senior management roles at Shire Plc (acquired by Takeda Pharmaceutical), including Senior Vice President of Finance, Division Chief Financial Officer for the Regenerative Medicine Division and Head of Investor Relations. Previously, she also worked at Amgen, Inc. (Nasdaq: AMGN), a global biopharmaceutical company, for 15 years, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms. Stelzer has served as a member of the board of directors of MBX Biosciences, Inc. (Nasdaq: MBX), a clinical stage biopharmaceutical company, since January 2026, Sionna Therapeutics (Nasdaq: SION), a clinical stage cystic fibrosis company, since 2024, PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company, since 2020, Surface Oncology, Inc. (Nasdaq: SURF), a clinical stage immune oncology company, from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals, a clinical stage neurology company from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management.

Jeffrey Albers: Jeffrey Albers自2023年11月起担任董事。他目前自2023年1月起在专注于生物技术公司投资的风险投资公司Atlas Venture担任风险合伙人。Albers先生于2021年6月至2025年7月担任全球精准治疗公司蓝图医药公司（纳斯达克：BPMC）的董事长，于2022年4月至2022年12月担任执行主席，并于2014年7月至2021年6月担任首席执行官、总裁兼董事。在2014年7月加入蓝图医药之前，Albers先生于2012年1月至2014年4月担任挪威生物技术公司Algeta ASA的总裁，负责监督美国业务。在加入Algeta ASA之前，2005年7月至2011年11月，Albers先生任职于健赞，这是一家生物技术公司，现在是赛诺菲 S.A.的全资子公司，最近担任美国血液学和肿瘤学事业部副总裁。Albers先生在Kymera Therapeutics, Inc.（纳斯达克：KYMR）和多家私营公司的董事会任职，此前曾于2017年7月至2023年9月在Magenta Therapeutics, Inc.（后更名为Dianthus Therapeutics，Inc.（纳斯达克：DNTH））的董事会任职。Albers先生获得了印第安纳大学的学士学位以及乔治城大学的工商管理硕士和法学博士学位。

Jeffrey Albers has served as a director since November 2023.He currently serves as Venture Partner at Atlas Venture, a venture capital firm focused on investment in biotechnology companies, since January 2023. Mr. Albers served as Chairman of Blueprint Medicines Corporation (Nasdaq: BPMC), a global precision therapy company, from June 2021 to July 2025, Executive Chairman from April 2022 to December 2022 and as Chief Executive Officer, President and Director from July 2014 to June 2021. Prior to joining Blueprint Medicines in July 2014, Mr. Albers was President of Algeta ASA, a Norwegian biotechnology company from January 2012 to April 2014, where he oversaw the U.S. business. Prior to Algeta ASA, from July 2005 to November 2011, Mr. Albers was at Genzyme Corporation, a biotechnology company that is now a wholly owned subsidiary of Sanofi S.A., most recently as Vice President of the U.S. hematology and oncology business unit. Mr. Albers serves on the board of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR) and several private companies, and previously served on the board of directors of Magenta Therapeutics, Inc. (which later became Dianthus Therapeutics, Inc. (Nasdaq: DNTH)) from July 2017 to September 2023. Mr. Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University.; Jeffrey Albers自2023年11月起担任董事。他目前自2023年1月起在专注于生物技术公司投资的风险投资公司Atlas Venture担任风险合伙人。Albers先生于2021年6月至2025年7月担任全球精准治疗公司蓝图医药公司（纳斯达克：BPMC）的董事长，于2022年4月至2022年12月担任执行主席，并于2014年7月至2021年6月担任首席执行官、总裁兼董事。在2014年7月加入蓝图医药之前，Albers先生于2012年1月至2014年4月担任挪威生物技术公司Algeta ASA的总裁，负责监督美国业务。在加入Algeta ASA之前，2005年7月至2011年11月，Albers先生任职于健赞，这是一家生物技术公司，现在是赛诺菲 S.A.的全资子公司，最近担任美国血液学和肿瘤学事业部副总裁。Albers先生在Kymera Therapeutics, Inc.（纳斯达克：KYMR）和多家私营公司的董事会任职，此前曾于2017年7月至2023年9月在Magenta Therapeutics, Inc.（后更名为Dianthus Therapeutics，Inc.（纳斯达克：DNTH））的董事会任职。Albers先生获得了印第安纳大学的学士学位以及乔治城大学的工商管理硕士和法学博士学位。; Jeffrey Albers has served as a director since November 2023.He currently serves as Venture Partner at Atlas Venture, a venture capital firm focused on investment in biotechnology companies, since January 2023. Mr. Albers served as Chairman of Blueprint Medicines Corporation (Nasdaq: BPMC), a global precision therapy company, from June 2021 to July 2025, Executive Chairman from April 2022 to December 2022 and as Chief Executive Officer, President and Director from July 2014 to June 2021. Prior to joining Blueprint Medicines in July 2014, Mr. Albers was President of Algeta ASA, a Norwegian biotechnology company from January 2012 to April 2014, where he oversaw the U.S. business. Prior to Algeta ASA, from July 2005 to November 2011, Mr. Albers was at Genzyme Corporation, a biotechnology company that is now a wholly owned subsidiary of Sanofi S.A., most recently as Vice President of the U.S. hematology and oncology business unit. Mr. Albers serves on the board of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR) and several private companies, and previously served on the board of directors of Magenta Therapeutics, Inc. (which later became Dianthus Therapeutics, Inc. (Nasdaq: DNTH)) from July 2017 to September 2023. Mr. Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University.

Tomas Kiselak: Tomas Kiselak自2023年6月起担任董事。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是一家与他于2016年4月共同创立的医疗保健投资公司。在加入Fairmount之前，Kiselak先生是RA Capital Management，LLC的董事总经理，该公司是一家医疗保健和生命科学投资公司。Kiselak先生目前自2020年10月起担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2023年7月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO），自2024年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得神经科学和经济学学士学位。

Tomas Kiselak has served as a director since June 2023. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) since October 2020 and as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since July 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, and Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2024, as well as several private companies. Mr. Kiselak previously served as a director for Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 to March 2025. He received a B.S. in neuroscience and economics from Amherst College.; Tomas Kiselak自2023年6月起担任董事。Kiselak先生是Fairmount Funds Management LLC的创始合伙人，这是一家与他于2016年4月共同创立的医疗保健投资公司。在加入Fairmount之前，Kiselak先生是RA Capital Management，LLC的董事总经理，该公司是一家医疗保健和生命科学投资公司。Kiselak先生目前自2020年10月起担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）的董事会主席，自2023年7月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年4月起担任Jade Biosciences，Inc.（纳斯达克：JBIO），自2024年9月起担任Zenas BioPharma，Inc.（纳斯达克：ZBIO），以及多家私营公司。Kiselak先生此前曾于2023年9月至2025年3月期间担任石竹治疗公司（纳斯达克：DNTH）的董事。他在阿默斯特学院获得神经科学和经济学学士学位。; Tomas Kiselak has served as a director since June 2023. Mr. Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr. Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) since October 2020 and as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since July 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, and Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2024, as well as several private companies. Mr. Kiselak previously served as a director for Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 to March 2025. He received a B.S. in neuroscience and economics from Amherst College.

Peter Harwin: Peter Harwin自2023年6月起担任董事。Harwin先生是Fairmount Funds Management LLC的创始合伙人，这是一家与他于2016年4月共同创立的医疗保健投资公司。在加入Fairmount之前，Harwin先生是Boxer Capital，LLC投资团队的成员，Boxer Capital，LLC是一家投资基金，隶属于位于圣地亚哥的Tavistock Group。Harwin先生还担任自2020年7月起担任董事的Cogent Biosciences, Inc.（纳斯达克：COGT）和自2025年6月起担任董事的Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会主席，并自2023年7月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年11月起担任Damora Therapeutics，Inc.（纳斯达克：DMRA）的董事，自2024年8月起担任Oruka Therapeutics，Inc.（纳斯达克：ORKA）和私营公司Paragon Therapeutics，Inc.（“Paragon”）的董事。Harwin先生此前曾于2020年10月至2025年3月期间担任Viridian Therapeutics, Inc.（纳斯达克VRDN）的董事。Harwin先生拥有埃默里大学的学士学位。

Peter Harwin has served as a director since June 2023. Mr. Harwin is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, Mr. Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT), where he has served as a director since July 2020 and Crescent Biopharma, Inc. (Nasdaq: CBIO), where he has served as a director since June 2025, and has served as a director of Apogee Therapeutics, Inc. (Nasdaq: APGE) since July 2023, Damora Therapeutics, Inc. (Nasdaq: DMRA) since November 2025, Oruka Therapeutics, Inc. (Nasdaq: ORKA) since August 2024 and Paragon Therapeutics, Inc. ("Paragon"), a private company. Mr. Harwin previously served as a director for Viridian Therapeutics, Inc. (Nasdaq VRDN) from October 2020 to March 2025. Mr. Harwin holds a B.B.A. from Emory University.; Peter Harwin自2023年6月起担任董事。Harwin先生是Fairmount Funds Management LLC的创始合伙人，这是一家与他于2016年4月共同创立的医疗保健投资公司。在加入Fairmount之前，Harwin先生是Boxer Capital，LLC投资团队的成员，Boxer Capital，LLC是一家投资基金，隶属于位于圣地亚哥的Tavistock Group。Harwin先生还担任自2020年7月起担任董事的Cogent Biosciences, Inc.（纳斯达克：COGT）和自2025年6月起担任董事的Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会主席，并自2023年7月起担任Apogee Therapeutics，Inc.（纳斯达克：APGE）的董事，自2025年11月起担任Damora Therapeutics，Inc.（纳斯达克：DMRA）的董事，自2024年8月起担任Oruka Therapeutics，Inc.（纳斯达克：ORKA）和私营公司Paragon Therapeutics，Inc.（“Paragon”）的董事。Harwin先生此前曾于2020年10月至2025年3月期间担任Viridian Therapeutics, Inc.（纳斯达克VRDN）的董事。Harwin先生拥有埃默里大学的学士学位。; Peter Harwin has served as a director since June 2023. Mr. Harwin is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co founded in April 2016. Prior to Fairmount, Mr. Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT), where he has served as a director since July 2020 and Crescent Biopharma, Inc. (Nasdaq: CBIO), where he has served as a director since June 2025, and has served as a director of Apogee Therapeutics, Inc. (Nasdaq: APGE) since July 2023, Damora Therapeutics, Inc. (Nasdaq: DMRA) since November 2025, Oruka Therapeutics, Inc. (Nasdaq: ORKA) since August 2024 and Paragon Therapeutics, Inc. ("Paragon"), a private company. Mr. Harwin previously served as a director for Viridian Therapeutics, Inc. (Nasdaq VRDN) from October 2020 to March 2025. Mr. Harwin holds a B.B.A. from Emory University.

Michael Henderson: Michael Henderson自2023年6月起担任董事。Henderson博士自2022年9月起担任生物技术公司Apogee Therapeutics，Inc.（纳斯达克：APGE）的首席执行官，并自2023年6月起担任其董事会成员。Henderson博士是一位经验丰富的生物技术主管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他监督了多家公司的创建，启动了大量的药物开发计划，并带领团队获得了两项FDA批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月期间担任商业阶段的生物制药公司BridgeBio Pharma，Inc.（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，识别和投资新技术，并负责业务发展和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。Henderson博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。Henderson博士还担任了BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，Henderson博士曾于2015年1月至2016年4月在全球管理咨询公司麦肯锡公司工作，在此之前，他于2011年8月共同创立了生物技术公司PellePharm，Inc.。Henderson博士此前曾于2021年2月至2024年8月在ARYA科学并购 Corp IV（纳斯达克：医疗保健）的董事会任职，该公司是一家专注于TERM3行业的特殊目的收购公司。亨德森博士在哈佛大学获得全球健康学士学位，在斯坦福大学获得医学博士学位。

Michael Henderson has served as a director since June 2023. Dr. Henderson has served as Chief Executive Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September 2022 as well as a member of its board of directors since June 2023. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson previously served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, from February 2021 to August 2024. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.; Michael Henderson自2023年6月起担任董事。Henderson博士自2022年9月起担任生物技术公司Apogee Therapeutics，Inc.（纳斯达克：APGE）的首席执行官，并自2023年6月起担任其董事会成员。Henderson博士是一位经验丰富的生物技术主管，在商业领导、药物开发和商业战略方面具有专长。迄今为止，他监督了多家公司的创建，启动了大量的药物开发计划，并带领团队获得了两项FDA批准。在加入Apogee之前，Henderson博士于2020年1月至2022年9月期间担任商业阶段的生物制药公司BridgeBio Pharma，Inc.（纳斯达克：BBIO）的首席商务官，负责推进BridgeBio的总体战略，识别和投资新技术，并负责业务发展和运营。在担任该职位之前，他曾担任BridgeBio资产收购、战略和运营高级副总裁两年，负责业务发展、战略和运营。Henderson博士于2016年4月加入BridgeBio，担任资产收购、战略和运营副总裁。Henderson博士还担任了BridgeBio多家子公司的首席执行官。在加入BridgeBio之前，Henderson博士曾于2015年1月至2016年4月在全球管理咨询公司麦肯锡公司工作，在此之前，他于2011年8月共同创立了生物技术公司PellePharm，Inc.。Henderson博士此前曾于2021年2月至2024年8月在ARYA科学并购 Corp IV（纳斯达克：医疗保健）的董事会任职，该公司是一家专注于TERM3行业的特殊目的收购公司。亨德森博士在哈佛大学获得全球健康学士学位，在斯坦福大学获得医学博士学位。; Michael Henderson has served as a director since June 2023. Dr. Henderson has served as Chief Executive Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September 2022 as well as a member of its board of directors since June 2023. Dr. Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio's Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson also served as the Chief Executive Officer of a number of BridgeBio's subsidiaries. Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he co founded PellePharm, Inc., a biotechnology company, in August 2011. Dr. Henderson previously served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, from February 2021 to August 2024. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.

Cameron Turtle: Cameron Turtle于2023年6月加入Spyre Therapeutics，Inc.担任首席运营官，并于2023年11月被任命为Spyre Therapeutics，Inc.首席执行官和董事。在加入公司之前，Turtle博士在2023年5月至2023年6月期间担任Pre-Merger Spyre的顾问。此前，他于2022年7月至2023年5月在生命科学投资公司Foresite Labs担任风险合伙人；于2021年1月至2022年4月担任生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席战略官；于2018年11月至2021年1月担任生物制药公司Eidos治疗TERM3（纳斯达克：EIDX）的首席商务官，在那里他领导了业务发展、投资者关系以及作为该公司推进一种治疗某种形式心力衰竭的研究药物的多项运营职能。在加入BridgeBio和Eidos之前，他是麦肯锡公司的顾问，曾与制药和医疗器械公司合作，主题包括并购、增长战略、临床试验战略和销售队伍优化。Turtle博士自2026年3月23日起担任生物技术公司Damora Therapeutics，Inc.（纳斯达克：DMRA）的董事会成员，并于2024年8月至2025年12月担任生物技术公司Oruka Therapeutics，Inc.（纳斯达克：ORKA）的董事会成员。Turtle博士获得了华盛顿大学生物工程荣誉学士学位和牛津大学圣约翰学院心血管医学博士学位。他是多个奖项的获得者，包括罗德奖学金、金水奖学金、福布斯30岁以下30岁和旧金山商业时报40岁以下40岁。

Cameron Turtle joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executive Officer and a director in November 2023. Prior to joining the Company, Dr. Turtle was an advisor to Pre Merger Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle has served as a member of the board of directors of Damora Therapeutics, Inc. (Nasdaq: DMRA), a biotechnology company, since March 23, 2026 and Oruka Therapeutics, Inc. (Nasdaq: ORKA), a biotechnology company, from August 2024 to December 2025. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John's College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30 and San Francisco Business Times 40 Under 40.; Cameron Turtle于2023年6月加入Spyre Therapeutics，Inc.担任首席运营官，并于2023年11月被任命为Spyre Therapeutics，Inc.首席执行官和董事。在加入公司之前，Turtle博士在2023年5月至2023年6月期间担任Pre-Merger Spyre的顾问。此前，他于2022年7月至2023年5月在生命科学投资公司Foresite Labs担任风险合伙人；于2021年1月至2022年4月担任生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席战略官；于2018年11月至2021年1月担任生物制药公司Eidos治疗TERM3（纳斯达克：EIDX）的首席商务官，在那里他领导了业务发展、投资者关系以及作为该公司推进一种治疗某种形式心力衰竭的研究药物的多项运营职能。在加入BridgeBio和Eidos之前，他是麦肯锡公司的顾问，曾与制药和医疗器械公司合作，主题包括并购、增长战略、临床试验战略和销售队伍优化。Turtle博士自2026年3月23日起担任生物技术公司Damora Therapeutics，Inc.（纳斯达克：DMRA）的董事会成员，并于2024年8月至2025年12月担任生物技术公司Oruka Therapeutics，Inc.（纳斯达克：ORKA）的董事会成员。Turtle博士获得了华盛顿大学生物工程荣誉学士学位和牛津大学圣约翰学院心血管医学博士学位。他是多个奖项的获得者，包括罗德奖学金、金水奖学金、福布斯30岁以下30岁和旧金山商业时报40岁以下40岁。; Cameron Turtle joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executive Officer and a director in November 2023. Prior to joining the Company, Dr. Turtle was an advisor to Pre Merger Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle has served as a member of the board of directors of Damora Therapeutics, Inc. (Nasdaq: DMRA), a biotechnology company, since March 23, 2026 and Oruka Therapeutics, Inc. (Nasdaq: ORKA), a biotechnology company, from August 2024 to December 2025. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John's College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30 and San Francisco Business Times 40 Under 40.

高管简历

中英对照 | 中文 | 英文

Cameron Turtle: Cameron Turtle自2018年1月以来一直担任我们的高级副总裁，投资组合管理和企业发展，并于2017年2月至2017年12月担任投资组合管理董事。Turtle先生自2017年2月起还曾在我们的子公司Eidos Therapeutics工作，目前担任首席商务官。Turtle先生曾于2017年2月至2018年3月担任我们的子公司Navire Pharmaceuticals，Inc.的业务开发和运营Vice President。从2016年8月至2017年1月，乌龟先生是麦肯锡公司的顾问。Turtle先生在华盛顿大学（University of Washington）以优异成绩获得生物工程学士学位，并获得哲学博士学位。他在牛津大学圣约翰学院（University of Oxford，St.John&8217；s College）获得心血管医学博士学位，在那里他曾是一名罗德学者。

Cameron Turtle has served as BridgeBio Pharma, Inc. Senior Vice President, Portfolio Management and Corporate Development, since January 2018 and served as a Director, Portfolio Management, from February 2017 to December 2017. Mr. Turtle has also worked for BridgeBio Pharma, Inc. subsidiary, Eidos Therapeutics, since February 2017 currently as the chief business officer. Mr. Turtle previously worked as vice president of business development and operations for BridgeBio Pharma, Inc. subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017 Mr. Turtle was a consultant at McKinsey & Company. Mr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John's College, where he was a Rhodes Scholar.; Cameron Turtle自2018年1月以来一直担任我们的高级副总裁，投资组合管理和企业发展，并于2017年2月至2017年12月担任投资组合管理董事。Turtle先生自2017年2月起还曾在我们的子公司Eidos Therapeutics工作，目前担任首席商务官。Turtle先生曾于2017年2月至2018年3月担任我们的子公司Navire Pharmaceuticals，Inc.的业务开发和运营Vice President。从2016年8月至2017年1月，乌龟先生是麦肯锡公司的顾问。Turtle先生在华盛顿大学（University of Washington）以优异成绩获得生物工程学士学位，并获得哲学博士学位。他在牛津大学圣约翰学院（University of Oxford，St.John&8217；s College）获得心血管医学博士学位，在那里他曾是一名罗德学者。; Cameron Turtle has served as BridgeBio Pharma, Inc. Senior Vice President, Portfolio Management and Corporate Development, since January 2018 and served as a Director, Portfolio Management, from February 2017 to December 2017. Mr. Turtle has also worked for BridgeBio Pharma, Inc. subsidiary, Eidos Therapeutics, since February 2017 currently as the chief business officer. Mr. Turtle previously worked as vice president of business development and operations for BridgeBio Pharma, Inc. subsidiary, Navire Pharmaceuticals, Inc., from February 2017 to March 2018. From August 2016 to January 2017 Mr. Turtle was a consultant at McKinsey & Company. Mr. Turtle received his B.S. with honors in bioengineering from the University of Washington and his D. Phil. in cardiovascular medicine from University of Oxford, St. John's College, where he was a Rhodes Scholar.

Heidy King Jones: Heidy King Jones于2020年8月加入Provention担任首席法务官。她在生物技术和制药行业拥有近13年的公司法律顾问和律师事务所经验。作为首席法务官，King-Jones女士支持Provention Bio公司坚持合规、公司治理、法律和企业风险管理最佳实践的承诺。在加入Provention之前，她曾担任Axcella Health，Inc.的高级副总裁and General Counsel（从2018年1月到2020年8月）。在加入Axcella之前，她从2013年7月到2018年1月在Sarepta Therapeutics担任越来越多的法律职务，包括公司法律部主管和Exondys51商业化的首席律师。King-Jones女士的职业生涯始于担任Ropes&Gray LLP’；S Securities&Public Company Practice Group的一员。她拥有达特茅斯学院（Dartmouth College）的学士学位和法学博士学位。来自康奈尔大学法学院。

Heidy King Jones joined Provention as its Chief Legal Officer "CLO" in August 2020. As Chief Legal Officer, Ms. King-Jones supports Provention Bio's commitment to upholding the best practices of compliance, corporate governance, and legal and enterprise risk management. Prior to joining Provention, Ms. King-Jones served as Senior Vice President and General Counsel of Axcella Health, Inc. where she worked from January 2018 to August 2020. Prior to Axcella, she held legal roles of increasing responsibility at Sarepta Therapeutics from July 2013 to January 2018 including head of Corporate Law Department and lead attorney for commercialization of Exondys 51. Ms. King-Jones started her career as a part of Ropes & Gray LLP's Securities & Public Company Practice Group. She holds a B.A. from Dartmouth College and a J.D. and LL.M. from Cornell Law School.; Heidy King Jones于2020年8月加入Provention担任首席法务官。她在生物技术和制药行业拥有近13年的公司法律顾问和律师事务所经验。作为首席法务官，King-Jones女士支持Provention Bio公司坚持合规、公司治理、法律和企业风险管理最佳实践的承诺。在加入Provention之前，她曾担任Axcella Health，Inc.的高级副总裁and General Counsel（从2018年1月到2020年8月）。在加入Axcella之前，她从2013年7月到2018年1月在Sarepta Therapeutics担任越来越多的法律职务，包括公司法律部主管和Exondys51商业化的首席律师。King-Jones女士的职业生涯始于担任Ropes&Gray LLP’；S Securities&Public Company Practice Group的一员。她拥有达特茅斯学院（Dartmouth College）的学士学位和法学博士学位。来自康奈尔大学法学院。; Heidy King Jones joined Provention as its Chief Legal Officer "CLO" in August 2020. As Chief Legal Officer, Ms. King-Jones supports Provention Bio's commitment to upholding the best practices of compliance, corporate governance, and legal and enterprise risk management. Prior to joining Provention, Ms. King-Jones served as Senior Vice President and General Counsel of Axcella Health, Inc. where she worked from January 2018 to August 2020. Prior to Axcella, she held legal roles of increasing responsibility at Sarepta Therapeutics from July 2013 to January 2018 including head of Corporate Law Department and lead attorney for commercialization of Exondys 51. Ms. King-Jones started her career as a part of Ropes & Gray LLP's Securities & Public Company Practice Group. She holds a B.A. from Dartmouth College and a J.D. and LL.M. from Cornell Law School.

Sheldon Sloan: Sheldon Sloan自2023年3月起担任Abivax Sa首席医疗官。他在学术界和生物制药行业拥有超过30年的经验，在胃肠病学和IBD领域拥有丰富的记录。从2022年3月到2023年1月，斯隆博士在辉瑞担任etrasimod UC项目负责人。2019年11月至2022年3月，斯隆博士在阿里那制药工作。1997年9月至2019年10月期间，斯隆博士在强生医疗事务、研发和科学政策部门担任不同的领导职务，包括IBD全球医疗事务负责人，领导CD和UC Stelara的全球发布战略和执行。他拥有芝加哥拉什医学院的医学博士学位和宾夕法尼亚大学的生物伦理学硕士学位。

Sheldon Sloan,has been Abivax Sa Chief Medical Officer since March 2023. He has over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. From March 2022 to January 2023, Dr. Sloan was Program Lead for etrasimod UC at Pfizer. From November 2019 to March 2022, Dr. Sloan worked for Arena Pharmaceuticals. Between September 1997 and October 2019, Dr. Sloan held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago and a Master of Bioethics from the University of Pennsylvania.; Sheldon Sloan自2023年3月起担任Abivax Sa首席医疗官。他在学术界和生物制药行业拥有超过30年的经验，在胃肠病学和IBD领域拥有丰富的记录。从2022年3月到2023年1月，斯隆博士在辉瑞担任etrasimod UC项目负责人。2019年11月至2022年3月，斯隆博士在阿里那制药工作。1997年9月至2019年10月期间，斯隆博士在强生医疗事务、研发和科学政策部门担任不同的领导职务，包括IBD全球医疗事务负责人，领导CD和UC Stelara的全球发布战略和执行。他拥有芝加哥拉什医学院的医学博士学位和宾夕法尼亚大学的生物伦理学硕士学位。; Sheldon Sloan,has been Abivax Sa Chief Medical Officer since March 2023. He has over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. From March 2022 to January 2023, Dr. Sloan was Program Lead for etrasimod UC at Pfizer. From November 2019 to March 2022, Dr. Sloan worked for Arena Pharmaceuticals. Between September 1997 and October 2019, Dr. Sloan held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago and a Master of Bioethics from the University of Pennsylvania.

Scott Burrows: Scott Burrows于2023年9月加入Spyre Therapeutics，Inc.，担任首席财务官。在加入Spyre之前，Burrows先生最近于2021年4月至2023年8月担任生物制药公司Arcutis Biotherapeutics, Inc.（纳斯达克：ARQT）的首席财务官，并于2019年5月至2021年4月担任财务副总裁，在那里他帮助领导Arcutis成功进行首次公开发行股票、进一步进行了几次股权和债务融资，并向一家完全整合的商业阶段公司过渡。在加入Arcutis之前，Burrows先生于2018年3月至2019年5月期间担任Shire，plc的国际投资者关系主管，Shire，plc是一家生物技术公司，于2019年被Takeda Pharmaceutical Company Limited收购。在其职业生涯的早期，他曾在安进公司工作了15年，在财务规划和分析、财务和投资者关系方面担任越来越多的职责。Burrows先生的职业生涯始于Arthur Andersen，担任顾问。Burrows先生还担任非营利组织Ventura County的Food Share的董事会成员。他在加州大学洛杉矶分校获得了学士和工商管理硕士学位，是一名持牌注册会计师（非在职）。

Scott Burrows joined as Spyre Therapeutics, Inc. Chief Financial Officer in September 2023. Prior to Spyre, Mr. Burrows most recently served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company, from April 2021 to August 2023 and as Vice President of Finance from May 2019 to April 2021, where he helped lead Arcutis through a successful initial public offering, several further equity and debt financings, and the transition to a fully integrated commercial stage company. Prior to Arcutis, Mr. Burrows was the head of international investor relations for Shire, plc, a biotechnology company that was acquired by Takeda Pharmaceutical Company Limited in 2019, from March 2018 to May 2019. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury and investor relations. Mr. Burrows began his career at Arthur Andersen as a consultant. Mr. Burrows also serves as on the board of directors of Food Share of Ventura County, a non profit organization. He earned his B.A. and M.B.A. from the University of California, Los Angeles, and is a licensed C.P.A. (inactive).; Scott Burrows于2023年9月加入Spyre Therapeutics，Inc.，担任首席财务官。在加入Spyre之前，Burrows先生最近于2021年4月至2023年8月担任生物制药公司Arcutis Biotherapeutics, Inc.（纳斯达克：ARQT）的首席财务官，并于2019年5月至2021年4月担任财务副总裁，在那里他帮助领导Arcutis成功进行首次公开发行股票、进一步进行了几次股权和债务融资，并向一家完全整合的商业阶段公司过渡。在加入Arcutis之前，Burrows先生于2018年3月至2019年5月期间担任Shire，plc的国际投资者关系主管，Shire，plc是一家生物技术公司，于2019年被Takeda Pharmaceutical Company Limited收购。在其职业生涯的早期，他曾在安进公司工作了15年，在财务规划和分析、财务和投资者关系方面担任越来越多的职责。Burrows先生的职业生涯始于Arthur Andersen，担任顾问。Burrows先生还担任非营利组织Ventura County的Food Share的董事会成员。他在加州大学洛杉矶分校获得了学士和工商管理硕士学位，是一名持牌注册会计师（非在职）。; Scott Burrows joined as Spyre Therapeutics, Inc. Chief Financial Officer in September 2023. Prior to Spyre, Mr. Burrows most recently served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company, from April 2021 to August 2023 and as Vice President of Finance from May 2019 to April 2021, where he helped lead Arcutis through a successful initial public offering, several further equity and debt financings, and the transition to a fully integrated commercial stage company. Prior to Arcutis, Mr. Burrows was the head of international investor relations for Shire, plc, a biotechnology company that was acquired by Takeda Pharmaceutical Company Limited in 2019, from March 2018 to May 2019. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury and investor relations. Mr. Burrows began his career at Arthur Andersen as a consultant. Mr. Burrows also serves as on the board of directors of Food Share of Ventura County, a non profit organization. He earned his B.A. and M.B.A. from the University of California, Los Angeles, and is a licensed C.P.A. (inactive).

Sheldon Sloan: Sheldon Sloan自2024年10月起担任Spyre Therapeutics，Inc.首席医疗官。Sloan博士最近于2023年3月至2024年8月担任生物制药公司Abivax S.A.（纳斯达克：ABVX）的首席医疗官，负责Leading Medical Strategy以支持先导3期计划、制定先导和后续化合物的生命周期战略、投资者界面、业务发展支持，以及构建包括临床开发、药物警戒、生物信息学、医学事务和临床药理学的3期医疗基础设施。2022年3月至2023年1月，Sloan博士在生物制药公司辉瑞，Inc.（NYSE：PFE）担任etrasimod UC副总裁兼项目负责人，负责领导etrasimod UC跨职能团队并监督NDA和MM提交。从2019年11月到2022年3月，Sloan博士在Arena Pharmaceuticals, Inc.担任etrasimod GI的副总裁兼项目负责人，该公司是一家在纳斯达克上市的生物制药公司，于2022年3月被TERM1收购，负责领导3期项目的跨功能etrasimod UC团队。1997年9月至2019年10月期间，Sloan博士在医药和医疗技术公司强生（NYSE：JNJ）担任医疗事务、研发和科学政策方面的不同领导职务，其中包括IBD的全球医疗事务负责人，领导Stelara的CD和UC的全球发布战略和执行。他拥有芝加哥拉什医学院的医学博士学位、宾夕法尼亚大学的生物伦理学硕士学位和伊利诺伊大学厄巴纳香槟分校的理学学士学位。Sloan博士目前在哥伦比亚大学生物伦理学硕士顾问委员会和德雷塞尔大学Dornsife公共卫生学院院长影响、进步和学习委员会任职。

Sheldon Sloan has served as Spyre Therapeutics, Inc. Chief Medical Officer since October 2024. Dr. Sloan most recently served as the Chief Medical Officer of Abivax S.A. (Nasdaq: ABVX), a biopharmaceutical company, from March 2023 to August 2024, where he was responsible for leading medical strategy to support the lead Phase 3 program, developing lifecycle strategy for lead and follow on compounds, investor interface, business development support, and building a Phase 3 medical infrastructure including Clinical Development, Pharmacovigilance, Bioinformatics, Medical Affairs and Clinical Pharmacology. From March 2022 to January 2023, Dr. Sloan was Vice President and Program Lead for etrasimod UC at Pfizer, Inc. (NYSE: PFE), a biopharmaceutical company, where he was responsible for leading the etrasimod UC cross functional team and overseeing NDA and MM submission. From November 2019 to March 2022, Dr. Sloan was Vice President and Program Lead for etrasimod GI at Arena Pharmaceuticals, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Pfizer in March 2022, where he was responsible for leading the cross functional etrasimod UC team for the Phase 3 program. Between September 1997 and October 2019, Dr. Sloan held different leadership positions at Johnson and Johnson (NYSE: JNJ), a pharmaceutical and medical technologies company, in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago, a Master of Bioethics from the University of Pennsylvania and a Bachelor of Science from University of Illinois Urbana Champaign. Dr. Sloan currently serves on the Columbia University Masters of Bioethics Advisory Board and the Drexel University Dornsife School of Public Health Dean's Impact, Advancement and Learning Council.; Sheldon Sloan自2024年10月起担任Spyre Therapeutics，Inc.首席医疗官。Sloan博士最近于2023年3月至2024年8月担任生物制药公司Abivax S.A.（纳斯达克：ABVX）的首席医疗官，负责Leading Medical Strategy以支持先导3期计划、制定先导和后续化合物的生命周期战略、投资者界面、业务发展支持，以及构建包括临床开发、药物警戒、生物信息学、医学事务和临床药理学的3期医疗基础设施。2022年3月至2023年1月，Sloan博士在生物制药公司辉瑞，Inc.（NYSE：PFE）担任etrasimod UC副总裁兼项目负责人，负责领导etrasimod UC跨职能团队并监督NDA和MM提交。从2019年11月到2022年3月，Sloan博士在Arena Pharmaceuticals, Inc.担任etrasimod GI的副总裁兼项目负责人，该公司是一家在纳斯达克上市的生物制药公司，于2022年3月被TERM1收购，负责领导3期项目的跨功能etrasimod UC团队。1997年9月至2019年10月期间，Sloan博士在医药和医疗技术公司强生（NYSE：JNJ）担任医疗事务、研发和科学政策方面的不同领导职务，其中包括IBD的全球医疗事务负责人，领导Stelara的CD和UC的全球发布战略和执行。他拥有芝加哥拉什医学院的医学博士学位、宾夕法尼亚大学的生物伦理学硕士学位和伊利诺伊大学厄巴纳香槟分校的理学学士学位。Sloan博士目前在哥伦比亚大学生物伦理学硕士顾问委员会和德雷塞尔大学Dornsife公共卫生学院院长影响、进步和学习委员会任职。; Sheldon Sloan has served as Spyre Therapeutics, Inc. Chief Medical Officer since October 2024. Dr. Sloan most recently served as the Chief Medical Officer of Abivax S.A. (Nasdaq: ABVX), a biopharmaceutical company, from March 2023 to August 2024, where he was responsible for leading medical strategy to support the lead Phase 3 program, developing lifecycle strategy for lead and follow on compounds, investor interface, business development support, and building a Phase 3 medical infrastructure including Clinical Development, Pharmacovigilance, Bioinformatics, Medical Affairs and Clinical Pharmacology. From March 2022 to January 2023, Dr. Sloan was Vice President and Program Lead for etrasimod UC at Pfizer, Inc. (NYSE: PFE), a biopharmaceutical company, where he was responsible for leading the etrasimod UC cross functional team and overseeing NDA and MM submission. From November 2019 to March 2022, Dr. Sloan was Vice President and Program Lead for etrasimod GI at Arena Pharmaceuticals, Inc., a Nasdaq listed biopharmaceutical company that was acquired by Pfizer in March 2022, where he was responsible for leading the cross functional etrasimod UC team for the Phase 3 program. Between September 1997 and October 2019, Dr. Sloan held different leadership positions at Johnson and Johnson (NYSE: JNJ), a pharmaceutical and medical technologies company, in Medical Affairs, Research and Development, and Science Policy, including Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago, a Master of Bioethics from the University of Pennsylvania and a Bachelor of Science from University of Illinois Urbana Champaign. Dr. Sloan currently serves on the Columbia University Masters of Bioethics Advisory Board and the Drexel University Dornsife School of Public Health Dean's Impact, Advancement and Learning Council.

Heidy King Jones: Heidy King Jones于2023年9月加入，担任Spyre Therapeutics，Inc.首席法务官和公司秘书。King Jones女士最近于2020年至2023年在生物制药公司Provention Bio, Inc.担任首席法务官和公司秘书，包括通过各种融资、批准TZield，该公司从临床阶段成功过渡到商业化阶段以及2023年4月被赛诺菲收购。在加入Provention Bio担任领导职务之前，她于2019年至2020年在生物技术公司Axcella Health Inc.担任高级副总裁、总法律顾问和公司秘书，并于2018年至2019年担任副总裁、法律和公司秘书，负责Axcella的公司法律职能和战略。2013年至2018年，她在Sarepta Therapeutics, Inc.（纳斯达克：SRPT）的法律部门担任越来越负责任的职位，包括作为公司法高级总监监督所有公司法事务。在Sarepta期间，她担任公司商业准备工作小组的成员，负责开发其首个产品Exondys51的合规计划、合同和其他法律工作.King Jones女士在Ropes & Gray LLP的证券与上市公司业务组开始了她的法律生涯，在那里她代表了制药、公用事业和技术行业的私营和上市公司。她拥有康奈尔大学法学院国际和比较法的法学博士和法学硕士学位，以及达特茅斯学院的学士学位。

Heidy King Jones joined as Spyre Therapeutics, Inc. Chief Legal Officer and Corporate Secretary in September 2023. Ms. King Jones most recently served as the Chief Legal Officer and Corporate Secretary at Provention Bio, Inc., a biopharmaceutical company, from 2020 to 2023, including through various financings, the approval of Tzield, the company's successful transition from clinical stage to commercial stage as well as its acquisition by Sanofi in April 2023. Prior to her leadership role at Provention Bio, she was a Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc., a biotechnology company, from 2019 to 2020 and as Vice President, Legal and Corporate Secretary from 2018 to 2019, where she was responsible for Axcella's corporate legal function and strategy. From 2013 to 2018, she held positions of increasing responsibility in the legal department at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), including overseeing all Corporate Law matters as Senior Director, Corporate Law. While at Sarepta, she served as a member of the company's commercial readiness working group and was responsible for the development of the compliance program, contract and other legal work for the launch of its first product, Exondys 51. Ms. King Jones began her legal career in the Securities & Public Companies Practice Group at Ropes & Gray LLP, where she represented private and publicly traded companies in the pharmaceutical, utility and technology industries. She holds a J.D. and LL.M in International and Comparative Law from Cornell Law School, and a B.A. from Dartmouth College.; Heidy King Jones于2023年9月加入，担任Spyre Therapeutics，Inc.首席法务官和公司秘书。King Jones女士最近于2020年至2023年在生物制药公司Provention Bio, Inc.担任首席法务官和公司秘书，包括通过各种融资、批准TZield，该公司从临床阶段成功过渡到商业化阶段以及2023年4月被赛诺菲收购。在加入Provention Bio担任领导职务之前，她于2019年至2020年在生物技术公司Axcella Health Inc.担任高级副总裁、总法律顾问和公司秘书，并于2018年至2019年担任副总裁、法律和公司秘书，负责Axcella的公司法律职能和战略。2013年至2018年，她在Sarepta Therapeutics, Inc.（纳斯达克：SRPT）的法律部门担任越来越负责任的职位，包括作为公司法高级总监监督所有公司法事务。在Sarepta期间，她担任公司商业准备工作小组的成员，负责开发其首个产品Exondys51的合规计划、合同和其他法律工作.King Jones女士在Ropes & Gray LLP的证券与上市公司业务组开始了她的法律生涯，在那里她代表了制药、公用事业和技术行业的私营和上市公司。她拥有康奈尔大学法学院国际和比较法的法学博士和法学硕士学位，以及达特茅斯学院的学士学位。; Heidy King Jones joined as Spyre Therapeutics, Inc. Chief Legal Officer and Corporate Secretary in September 2023. Ms. King Jones most recently served as the Chief Legal Officer and Corporate Secretary at Provention Bio, Inc., a biopharmaceutical company, from 2020 to 2023, including through various financings, the approval of Tzield, the company's successful transition from clinical stage to commercial stage as well as its acquisition by Sanofi in April 2023. Prior to her leadership role at Provention Bio, she was a Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc., a biotechnology company, from 2019 to 2020 and as Vice President, Legal and Corporate Secretary from 2018 to 2019, where she was responsible for Axcella's corporate legal function and strategy. From 2013 to 2018, she held positions of increasing responsibility in the legal department at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), including overseeing all Corporate Law matters as Senior Director, Corporate Law. While at Sarepta, she served as a member of the company's commercial readiness working group and was responsible for the development of the compliance program, contract and other legal work for the launch of its first product, Exondys 51. Ms. King Jones began her legal career in the Securities & Public Companies Practice Group at Ropes & Gray LLP, where she represented private and publicly traded companies in the pharmaceutical, utility and technology industries. She holds a J.D. and LL.M in International and Comparative Law from Cornell Law School, and a B.A. from Dartmouth College.

Cameron Turtle: Cameron Turtle于2023年6月加入Spyre Therapeutics，Inc.担任首席运营官，并于2023年11月被任命为Spyre Therapeutics，Inc.首席执行官和董事。在加入公司之前，Turtle博士在2023年5月至2023年6月期间担任Pre-Merger Spyre的顾问。此前，他于2022年7月至2023年5月在生命科学投资公司Foresite Labs担任风险合伙人；于2021年1月至2022年4月担任生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席战略官；于2018年11月至2021年1月担任生物制药公司Eidos治疗TERM3（纳斯达克：EIDX）的首席商务官，在那里他领导了业务发展、投资者关系以及作为该公司推进一种治疗某种形式心力衰竭的研究药物的多项运营职能。在加入BridgeBio和Eidos之前，他是麦肯锡公司的顾问，曾与制药和医疗器械公司合作，主题包括并购、增长战略、临床试验战略和销售队伍优化。Turtle博士自2026年3月23日起担任生物技术公司Damora Therapeutics，Inc.（纳斯达克：DMRA）的董事会成员，并于2024年8月至2025年12月担任生物技术公司Oruka Therapeutics，Inc.（纳斯达克：ORKA）的董事会成员。Turtle博士获得了华盛顿大学生物工程荣誉学士学位和牛津大学圣约翰学院心血管医学博士学位。他是多个奖项的获得者，包括罗德奖学金、金水奖学金、福布斯30岁以下30岁和旧金山商业时报40岁以下40岁。

Cameron Turtle joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executive Officer and a director in November 2023. Prior to joining the Company, Dr. Turtle was an advisor to Pre Merger Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle has served as a member of the board of directors of Damora Therapeutics, Inc. (Nasdaq: DMRA), a biotechnology company, since March 23, 2026 and Oruka Therapeutics, Inc. (Nasdaq: ORKA), a biotechnology company, from August 2024 to December 2025. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John's College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30 and San Francisco Business Times 40 Under 40.; Cameron Turtle于2023年6月加入Spyre Therapeutics，Inc.担任首席运营官，并于2023年11月被任命为Spyre Therapeutics，Inc.首席执行官和董事。在加入公司之前，Turtle博士在2023年5月至2023年6月期间担任Pre-Merger Spyre的顾问。此前，他于2022年7月至2023年5月在生命科学投资公司Foresite Labs担任风险合伙人；于2021年1月至2022年4月担任生物制药公司BridgeBio Pharma（纳斯达克：BBIO）的首席战略官；于2018年11月至2021年1月担任生物制药公司Eidos治疗TERM3（纳斯达克：EIDX）的首席商务官，在那里他领导了业务发展、投资者关系以及作为该公司推进一种治疗某种形式心力衰竭的研究药物的多项运营职能。在加入BridgeBio和Eidos之前，他是麦肯锡公司的顾问，曾与制药和医疗器械公司合作，主题包括并购、增长战略、临床试验战略和销售队伍优化。Turtle博士自2026年3月23日起担任生物技术公司Damora Therapeutics，Inc.（纳斯达克：DMRA）的董事会成员，并于2024年8月至2025年12月担任生物技术公司Oruka Therapeutics，Inc.（纳斯达克：ORKA）的董事会成员。Turtle博士获得了华盛顿大学生物工程荣誉学士学位和牛津大学圣约翰学院心血管医学博士学位。他是多个奖项的获得者，包括罗德奖学金、金水奖学金、福布斯30岁以下30岁和旧金山商业时报40岁以下40岁。; Cameron Turtle joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executive Officer and a director in November 2023. Prior to joining the Company, Dr. Turtle was an advisor to Pre Merger Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle has served as a member of the board of directors of Damora Therapeutics, Inc. (Nasdaq: DMRA), a biotechnology company, since March 23, 2026 and Oruka Therapeutics, Inc. (Nasdaq: ORKA), a biotechnology company, from August 2024 to December 2025. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John's College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30 and San Francisco Business Times 40 Under 40.

今开：--	昨收：--	最高：--	最低：--
成交量：--万手	市盈率：--	总市值($)：--	换手率：--

用户名：		快速注册
密码：		忘记密码?

SYRE
-- -- --

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

董事介绍

高管介绍

董事简历

高管简历

您尚未登录，请登录后再添加自选股！

SYRE -- -- --

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

董事介绍

高管介绍

董事简历

高管简历

您尚未登录，请登录后再添加自选股！

SYRE
-- -- --

首页概览公司概况财务分析高管介绍股本结构公司新闻